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Kisspeptin-10 Is a Potent Stimulator of LH and
Increases Pulse Frequency in Men
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R. P. Millar,* and R. A. Anderson*
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and Division of Reproductive and Developmental Sciences (R.A.A.), Centre for Reproductive Biology, The
Queen’s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, United Kingdom;
Endocrine Research Unit (J.D.V.), Center for Translational Science Activities, Mayo Clinic, Rochester,
Minnesota 55905; Medical Research Council/University of Cape Town (R.P.M.), Receptor Biology and
Reproductive Health Group, Division of Medical Biochemistry, University of Cape Town, Observatory
7925, 7701 Cape Town, South Africa; and Mammal Research Institute (R.P.M.), University of Pretoria,
Pretoria 0028, South Africa
Context: Kisspeptins stimulate GnRH and thus gonadotropin secretion. Kisspeptin-10 is the min-
imal kisspeptin sequence with full intrinsic bioactivity, but it has not been studied in man.
Objective: We investigated our hypothesis that kisspeptin-10 increases GnRH and thus LH pulse
frequency.
Design and Participants: The dose response of kisspeptin-10 was investigated by administering iv
bolus doses (0.01–3.0 g/kg) and vehicle to healthy men. Effects on LH pulse frequency and size
were determined by deconvolution analysis during infusion of kisspeptin-10 for up to 22.5 h.
Results: Intravenous bolus kisspeptin-10 resulted in a rapid and dose-dependent rise in serum LH
concentration, with maximal stimulation at 1 g/kg (4.1 0.4 to 12.4 1.7 IU/liter at 30 min, P
0.001, n 6). Administration of 3 g/kg elicited a reduced response vs. 1 g/kg (P 0.05). Infusion
of kisspeptin-10 at 4g/kg  h for 22.5 h elicited an increase in LH fromameanof 5.4 0.7 to 20.8
4.9 IU/liter (n4;P0.05)andserumtestosterone increasedfrom16.62.4 to24.02.5nmol/liter
(P  0.001). LH pulses were obscured at this high rate of secretion, but a lower dose infusion of
kisspeptin-10 (1.5g/kg  h) increasedmean LH from5.2 0.8 to 14.1 1.7 IU/liter (n 4; P 0.01)
and increased LH pulse frequency from0.7 0.1 to 1.0 0.2 pulses/h (P 0.05) and secretory burst
mass from 3.9  0.4 to 12.8  2.6 IU/liter (P  0.05).
Conclusions: Kisspeptin-10 boluses potently evoke LH secretion in men, and continuous infusion
increases testosterone, LH pulse frequency, and pulse size. Kisspeptin analogues have therapeutic
potential as regulators of LH and thus testosterone secretion. (J Clin Endocrinol Metab 96:
E1228–E1236, 2011)
The central role of GnRH (LHRH) in regulating repro-duction by stimulating the secretion of pituitary go-
nadotropins (LH and FSH) is well established (1). Kiss-
peptin, a hypothalamic neuropeptide encoded by the
KISS1 gene, has recently emerged as a key central regula-
tor of GnRH secretion. Kisspeptin signaling is obligatory
for normal pubertalmaturation, as evidenced by absent or
advanced pubertal development in individuals with mu-
tations in genes encoding kisspeptin (2) and its receptor
[KISS1R; also known as G protein-coupled receptor
(GPR) 54] (3–6). Administration of exogenous kisspeptin
stimulates LH secretion in both men and women (7–9).
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Human studies of kisspeptin have hitherto used the 54-
aminoacidpeptide, kisspeptin-54 (7–10).Kisspeptin-54 is
cleaved from the 145-amino acid precursor polypeptide
encoded by KISS1 and is further processed to 14, 13, and
10 amino acid (kisspeptin-10) sequences, all sharing the
same C-terminal decapeptide RFAmide (arginine-ami-
dated phenylalanine) sequence (11). Although kisspep-
tin-10 has intrinsic bioactivity similar to the longer kiss-
peptin fragments (11), it is also characterized by a shorter
half-life and more rapid onset of action after iv adminis-
tration in rodents (12). Kisspeptin-10 also has greater po-
tential for pharmaceutical development because both ago-
nists (13) and antagonists (14, 15) have been developed
based on its decapeptide sequence. However, there have
been no studies on the activity of kisspeptin-10 in humans.
Alterations in GnRH pulsatility and thus LH secretion
are a feature of a number of reproductive disorders. Indi-
viduals with some forms of male hypogonadism (16) and
hypothalamic amenorrhea (17) show decreased pulse fre-
quency, whereas women with polycystic ovarian syn-
drome show an increase (18). However, neuroendocrine
mechanisms underpinningGnRHpulse generation are yet
to be fully delineated (19). Experimental animals exposed
to kisspeptin antagonists demonstrate decreased LH pul-
satile secretion, suggesting that kisspeptin modulates
GnRH pulse frequency (20). Although administration of
kisspeptin-54 acutely stimulates LH secretion in men and
women (7, 8), it is unclear whether this is mediated by a
change in LH pulse frequency, which would indicate an
underlying stimulatory effect on GnRH pulse frequency.
In these first-in-human studies of kisspeptin-10, we
aimed to establish the dose dependency and time course of
stimulation of LH secretion after iv bolus doses of kiss-
peptin-10 and to compare the magnitude of this stimu-
latedLHsecretionwith that after amaximally stimulatory
doseofGnRH.Having established that kisspeptin-10 is an
effective LH secretagogue, we further investigated the ef-
fects of infusion of kisspeptin-10 on LH pulsatility. We
also examined whether high-dose continuous infusion of
kisspeptin-10 induces tachyphylaxis of LH response, as
previously suggested in a male primate model (21).
Participants and Methods
Participants
Sixhealthymale volunteers tookpart in acutekisspeptin stim-
ulation studies and four healthy males in each of the infusion
studies. All volunteers provided informed written consent, and
the study was approved by a local research ethics committee
(Lothian Research Ethics Committee References 09/S1101/23
and 09/S1101/67). The age of healthy male participants was
35.6  3.4 (mean  SEM) and body mass index was 26.1  0.8
kg/m2, all ofwhomhad aminimumbilateral testicular volumeof
40ml, normal physical examination, and normal secondary sex-
ual characteristics. Baseline full blood count, renal function, liver
function, and electrolytes were within normal limits.
Study drugs
Kisspeptin-10was custom synthesized underGMP standards
(BachemGmBH,Weil amRhein, Germany). Puritywas assessed
by HPLC at 97% with a mass balance of 98.8%. For each par-
ticipant, kisspeptin-10 was made up within the hour before in-
jection by diluting 1 mg of lyophilized kisspeptin-10 in 5 ml
sterile normal saline. Stability of kisspeptin-10 in solution was
assessed by in vitro receptor binding studies comparing prein-
cubated and freshly constituted 0.2 mg/ml solution (data not
shown). A bolus of 0.5 ml sterile normal (0.9%) saline was in-
jected as vehicle. Commercially available GnRH (Relefact;
Sanofi Aventis, Frankfurt, Germany) was used for GnRH
stimulation.
Protocols
Kisspeptin-10 dose response study
This study was designed to assess the magnitude and dose
dependency of gonadotropin secretion in response to six iv bolus
doses (0.01, 0.03, 0.1, 0.3, 1.0, and 3.0 g/kg) of kisspeptin-10
or vehicle (normal saline).
All volunteers attended the study in a fasting state, and all
visits commenced between 0800 and 0900 h to avoid diurnal
bias. Blood sampleswere obtained through an indwelling iv can-
nulae before (60, 45, 30, 20, and 10 min and immediately) and
after (10, 20, 30, 45, 60, 75, and90min) kisspeptin-10 or vehicle
administration. Doses were administered in increasing order for
safety reasons and visits were at least 1 wk apart. All volunteers
received at least four doses and four volunteers received all doses.
Participants were blinded to the dose of kisspeptin-10.
Blood pressure, pulse, and peripheral oxygen saturations
weremeasured every3minwith standardautomated techniques.
Full blood count, serum electrolytes, liver function, and renal
function were checked at each visit.
High-dose kisspeptin-10 iv infusion
This study was designed to assess LH secretion and potential
desensitization of kisspeptin-KISS1R with a continuous high-
dose infusion of kisspeptin-10.
After an overnight fast, four volunteers attended our clinical
research facility for a 34-h supervised stay. Blood samples were
collected at 10-min intervals for two12-h periods on consecutive
days and hourly overnight. After 9 h of baseline sampling, 3
g/kg of kisspeptin-10 (the highest dose previously investigated)
was administered as an iv bolus and a continuous iv infusion of
kisspeptin-10 (Crono PCA; Cane, Rivoli, Italy) commenced 90
min later at 4g/kg  h.This infusion rate,maintained for 22.5h,
was selected to aim to give a comparable hourly dose to the
maximally effective bolus doses, bearing in mind the expected
short half-life of kisspeptin-10. A 100-g/kg iv bolus of GnRH
was administered 60 min before the end of the infusion.
Serum LH during the 9-h baseline frequent sampling period
was compared with the corresponding 9-h frequent sampling
period on the second day of the study during the iv infusion of
kisspeptin-10. In addition, we compared the mean LH values
observed in the initial 90 min of kisspeptin-10 infusion with the
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mean LH values observed in the final 90 min of infusion before
GnRH administration to identify any potential tachyphylaxis.
Comparisons were also made between mean LH over the 60
min before GnRH administration and the peak LH 30 min af-
terward. Serum testosterone was analyzed at 30-min intervals
during the two 9-h frequent sampling periods before and dur-
ing the infusion.
All subjects were provided with standardized meals through-
out the study and a period of overnight fast maintained between
2200 and 0900 h. Full blood count, electrolytes, liver function,
and renal function were checked at the beginning of the study,
24 h later, and at the end of the study.
Pulse frequency study
As there was an apparent increase in LH pulse frequency
during the high-dose kisspeptin-10 infusion, we examined this
further using a lower dose of kisspeptin-10.
Four healthy men attended our clinical research facility for
two visits 5 d apart for 10-min blood sampling. At the first visit,
baselineLHpulsatilitywasassessedovera9-hperiod.During the
second visit, an iv infusion of kisspeptin-10was administered for
9 h at 1.5 g/kg  h after an hour of baseline sampling. Subjects
were provided with standardized meals during the study visits.
Hormone assays
Blood sampleswere centrifuged immediately at4Cfor10min
at 3000 rpm and serum frozen at20 C until analysis. LH and
FSHwere determined by ELISA and testosterone by RIA as pre-
viously described (22). Interassay coefficient of variation for all
hormonal assays was less than 5% at the concentrations mea-
sured. Intraassay coefficient of variation of LH was 2.9%. All
samples from each of the study visits were analyzed together in
duplicate.
Statistical analysis
For the dose-finding study, 60-min mean LH and FSH con-
centrations and area under the curve (AUC; by trapezoid inte-
gration)beforeandafter thekisspeptin-10boluswere calculated.
Variance in mean LH and AUC values in the dose-response
study was analyzed by ANOVA followed by Tukey’s simulta-
neous test. Student’s t test was used to analyze changes in mean
LH,FSH,and testosterone concentrations in the infusion studies.
LH pulses were identified using a deconvolution algorithm
using cluster analysis with 93% sensitivity and specificity on
blinded data and basal, pulsatile, and total LH secretion calcu-
lated (23). Paired Student’s t test was used to assess changes in
pulse frequency.
Data are presented asmean SEM. A two-sided P 0.05was
regardedas statistically significant for all analyses.The statistical
software packageMinitab 16 (Minitab Ltd., Coventry, UK) was
used.
Results
Kisspeptin-10 dose-response study
Intravenous injections of kisspeptin-10 elicited a rapid
increase in LH in all volunteers, with peak concentrations
seen by 45 min after injection for all doses studied. The
maximum LH stimulation was seen after the 1-g/kg bo-
lus, achieving peak (12.4  1.7 IU/liter) concentration at
30 min (Fig. 1A).
There was a clear dose-dependent increase in LH con-
centrations in response to kisspeptin-10 (P  0.0001).
Statistically significant increases were observed after
the 0.03-, 0.1-, 0.3-, and 1-g/kg bolus doses (P 
FIG. 1. Gonadotropin response to acute administration of kisspeptin-
10 to normal men (n  6). A, Serum LH concentration in response to 1
g/kg kisspeptin-10 (filled circles), 3 g/kg kisspeptin-10 (filled
triangles), or vehicle (open circles) administered to healthy volunteers
at time 0. B,  AUC (60 min) of LH after kisspeptin-10 and vehicle
administration. C,  AUC (60 min) of FSH after kisspeptin-10 and
vehicle administration. Mean  SEM. *, P  0.05 vs. vehicle.
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0.01). There was, however, no significant increase in
LH concentration after the highest dose administered
(3.0 g/kg), and the mean LH after this dose was sig-
nificantly less than after the 0.3- and 1-g/kg doses
(both P  0.05). Calculation of the AUC over 60 min
following the kisspeptin-10 administration showed a
similar pattern, with the 0.1-, 0.3-, and 1-g/kg doses
achieving statistically significant changes compared
with vehicle (Fig. 1B).
FSH secretion also increased dose dependently after
kisspeptin-10 administration (P 0.012). The largest in-
crease was observed with 1 g/kg in which the mean 60-
min FSH rose from 4.6  1.0 to 5.3  1.0 IU/liter. In-
creases were seen in the AUC of FSH after 0.3 and 1g/kg
kisspeptin-10, with 3 g/kg again not resulting in a sig-
nificant increase in FSH concentration
(Fig. 1C). Serum testosterone concen-
trations showed no statistically signif-
icant change with any of the doses
studied (data not shown).
Blood pressure, heart rate, periph-
eral oxygenation, liver function, renal
function, hemoglobin, mean corpuscu-
lar volume, and electrolytes remained
stable in all subjects throughout the
study period. No adverse events were
reported.
Kisspeptin-10 continuous infusion
studies
Infusion of 4g/kg  h kisspeptin-10
resulted in sustained increases in LH
concentration. The LH profiles ob-
served in the four individual study sub-
jects are represented in Fig. 2. A bolus
injection of 3 g/kg kisspeptin-10 re-
sulted in an increase inLH to13.61.7
IU/liter (P  0.05 vs. baseline) at 30
min. Continuous kisspeptin-10 infu-
sion (4 g/kg  h) resulted in a further
increase in LH secretion in all subjects,
which was sustained throughout the
22.5 h of the infusion.Mean LHduring
kisspeptin-10 infusion was 20.9  4.9
vs. 5.5  0.8 IU/liter over the 9-h pre-
treatment period (P  0.05, Fig. 3A).
Mean LH concentrations in the final
90 min of infusion (23.9 6.8 IU/liter)
was comparable with that in the first
90 min of infusion (16.3  2.8 IU/
liter, P  0.34). These data therefore
do not indicate tachyphylaxis of the
LH response to kisspeptin-10 admin-
istration at this dose and duration of exposure.
Intravenous administration of 100 g bolus of GnRH
60 min before the end of the kisspeptin-10 infusion in-
creased LH furtherwith a peak of 89.3 6.1 IU/liter. This
stimulatory effect ofGnRHwas at least 2.5-fold greater in
all subjects than the peak LHobservedwith the iv bolus of
kisspeptin-10 (13.61.7 IU/liter,P0.001) and thepeak
LH achieved during kisspeptin-10 infusion (28.7  7.0
IU/liter, P  0.01).
Analysis of LH pulse frequency during the 9-h baseline
sampling and the corresponding 9-h period on the second
day of infusion was performed. Characteristic pulsatile
LH secretion was observed in all four subjects at baseline
but was not well defined during kisspeptin-10 infusion.
FIG. 2. Serum LH profiles of four individual subjects receiving 4 g/kg  h kisspeptin-10
infusion (black bar) after 9 h baseline sampling and 3 g/kg iv bolus administered at 9 h
(black arrow). Serum samples were obtained at 10 min intervals except overnight when
samples were obtained hourly. Note the difference in scale between individual subjects.
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Nevertheless, deconvolution analysis showed an in in-
crease in pulse frequency in three subjects (from0.4 to 0.6,
0.6 to 0.8, and 0.6 to 1.2 pulses/h, Fig. 2, A–C, respec-
tively), whereas one subject showed a slight decrease from
0.7 to 0.6 pulse/h (Fig. 2D), giving amean pulse frequency
of 0.6  0.1 pulses/h at baseline and 0.8  0.2 during
kisspeptin-10 infusion (P  ns).
AlthoughFSHshowed an increase in all subjects during
infusion of 4 g/kg  h kisspeptin-10, this was not statis-
tically significant (2.7 0.8 to 5 2.0 IU/liter, P 0.17,
Fig. 3B), whereas testosterone concentration significantly
increased from 16.6  2.4 to 24.0  2.5 nmol/liter (P 
0.001, Fig. 3C).
To investigate further whether continuous kisspep-
tin-10 exposure increases LH pulse frequency, we infused
a lower dose of 1.5 g/kg  h for 9 h. Mean LH increased
significantly from 5.2 0.8 IU/liter at baseline to 14.1
1.7 IU/liter during kisspeptin-10 infusion (P  0.01, n 
4, Fig. 4). LH showed a steady increase throughout the
course of the infusion, increasing from 7.2  2.3 IU/liter
in the first 90 min of infusion to 20.4 3.5 IU/liter in the
last 90 min (P  0.05, Fig. 4).
Deconvolution analysis demonstrated an increase in
LH pulse frequency in all subjects, with a mean increase
from 0.7  0.1 to 1.0  0.2 pulses/h (P  0.01) during
kisspeptin-10 infusion at 1.5g/kg  h (Fig. 4E). Secretory
mass of LH per pulse also increased in all subjects during
the infusion, from 3.9  0.4 to 12.8  2.6 IU/liter (P 
0.05, Fig 4F). Pulsatile LH secretion increased as a pro-
portion of total LH secretion in all subjects from 41.3 
5.7 to 69.5  5.9% during the infusion.
SerumFSHalso increasedprogressively during the low-
er-dose kisspeptin-10 infusion. FSH observed during the
final 90 min of the infusion (6.6  0.8 IU/liter) showed a
significant increase from the first 90 min (3.8  0.8 IU/
liter, P  0.05) of the infusion and baseline (3.9  0.7
IU/liter, P  0.05).
Discussion
We have demonstrated that iv administration of kisspep-
tin-10 boluses result in potent and dose-dependent stim-
ulation of LH secretion in healthy men. Doses of kisspep-
tin-10 as low as 0.03 g/kg (23 pmol/kg) elicited a
significant rise in LH when compared with vehicle, dem-
onstrating the high potency of kisspeptin-10. This is in
keeping with data from experimental animals where in-
tracerebroventricular doses of kisspeptin as small as 1
fmol effected robust LH stimulation (24). Central rather
than pituitary mediation of the effect of kisspeptin on LH
secretion has been demonstrated by abolition of the effect
of kisspeptin by pretreatment with a GnRH antagonist
(24–26).
The 2.5-fold increase in serum LH from baseline ob-
served after kisspeptin bolus administration in our study
is comparable with that observed in men administered
equimolar doses of kisspeptin-54 as short infusions (7).
Moreover, as inhuman studies usingkisspeptin-54 (7), the
stimulatory effect of kisspeptin-10 on LH secretion in our
study was also markedly more pronounced than that on
FSH secretion. Early animal studies suggested stimulatory
effects on LH and testosterone secretion were seen only
with the longer kisspeptin peptide, kisspeptin-54, and not
shorter forms (27). However, in vivo rodent data have
subsequently shown equal potency of kisspeptin-10 and
kisspeptin-54 (24, 28), and in in vitro binding assays, both
peptides show equal affinity at the KISS1R (11). Our re-
FIG. 3. Gonadotropin and testosterone response to infusions of 4 g/kg
of kisspeptin-10 (n 4). A, Mean serum LH before and during kisspeptin-
10 infusion. B, Mean serum FSH before and during kisspeptin-10 infusion.
C, Mean serum testosterone before and during kisspeptin-10 infusion.
Error bars represent SEM. *, P 0.05; ***, P 0.001.
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sults demonstrate that the 10 amino acid form of kisspep-
tin is a potent LH secretagogue in vivo in humans.
Although there was a clear dose dependency of LH
response to increasing doses of kisspeptin-10 up to 1 g/
kg, the 3-g/kg (2.3 nmol/kg) bolus dose did not elicit a
statistically significant increase when compared with ve-
hicle, andmean and peakLHconcentration after this dose
was lower than corresponding values after 0.3 and 1 g/
kg. This phenomenon has not been reported before after
bolus administration of kisspeptin, but continuous infu-
sion of kisspeptin-10 in primates (21) and repeated sc ad-
ministration of kisspeptin-54 in human subjects with hy-
pothalamic amenorrhea (9) resulted in tachyphylaxis. The
kisspeptin receptor KISS1R is known to desensitize rap-
idly in vitro (29), raising the possibility of rapid hypotha-
lamic desensitization. Although such desensitization is a
parsimonious explanation for the decreased response ob-
served here, desensitization has to be occurring rapidly
after kisspeptin-10 administration before maximal stim-
ulation of gonadotrophs is achieved. Because the fast half-
life of LH in healthy men is 18 min (30), lower peak LH
after the3g/kgwould suggest that thegonadotrophstim-
ulation was submaximal.
An alternative explanation for this
observation is that at high concentra-
tions, kisspeptin-10 may stimulate an-
other RF-amide receptor with an inhib-
itory effect on GnRH or LH secretion.
Kisspeptin-10, at nanomolar concentra-
tions, has been shown to bind and acti-
vate the gonadotropin inhibitory hor-
mone (GnIH) receptor [GPR147,
NPFFR1 (neuropeptide FF receptor 1)]
(31), which is expressed both in the hy-
pothalamus and on gonadotropes (32).
Nanomolar plasma concentrations of
kisspeptin were achieved after sc admin-
istrationof doses of kisspeptin-54 similar
to the kisspeptin-10 used in our study
(8). However, although peak plasma
kisspeptin-10 concentrations after the
3-g/kg bolus may have been sufficient
to activateGnIHreceptors, there is little
evidence for a functional role for GnIH
in humans, and in vivo studies in sheep
(33) would suggest that its effects are rel-
atively modest, and it is not possible to
exclude an effect of GnIH receptor in-
volvement in the infusion studies. The
reduced stimulatory efficacy of kiss-
peptin-10 at high concentrations de-
mands careful dosing in any potential
therapeutic applications.
Importantly, our studies demonstrate the novel phe-
nomenon that continuous infusion of kisspeptin-10 in-
creases LH pulse frequency. Along with increased secre-
tory mass in individual pulses, this increase in pulse
frequency resulted in pulsatile secretion contributing to a
higher proportion of total LH secreted. Data from other
investigators have not shown that GnRH pulse frequency
is increasedbyanacute bolus of kisspeptin (34), indicating
the need for continuing kisspeptin stimulation to study its
influence on GnRH pulse frequency. The dependency of
LH pulsatility on pulsatile GnRH secretion (1, 35) is well
established, and kisspeptin has been shown to directly
stimulate GnRH secretion (36) with electrophysiological
studies showing intense and prolonged activation of ro-
dent GnRH neurons by kisspeptin-10 (37). There is a
marked stochastic increase in LH when kisspeptin is ap-
plied to the hypothalamic arcuate nucleus in rodents,
whichmight reflect an acceleration of LH pulse frequency
(20), and a kisspeptin antagonist decreases LH pulse fre-
quency in thismodel (20). Systemic administrationofkiss-
peptin-10 in our study prevents us from concluding
whether this increase in LH (and by inference GnRH)
FIG. 4. Gonadotrophin response to 9-h iv infusion of 1.5 g/kg kisspeptin-10 (n  4). A–D,
LH profiles from individual subjects during baseline (closed circles) and kisspeptin-10 infusion
(open triangles) visits. Note the difference in scale between individual subjects. E, Mean LH
pulse frequency during baseline and kisspeptin-10 infusion visits. F, Secretory mass of LH per
pulse during baseline and kisspeptin infusion visits. Error bars represent SEM. *, P  0.05.
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pulse frequency is mediated by a direct effect on GnRH
neurons (19) or through stimulation of the hypothalamic
pulse generator (38). However, we have demonstrated
that LH pulsatility is dependent on kisspeptin, increasing
significantly during continuous administration.However,
it is possible that endogenous release of kisspeptin is pul-
satile, and pulsatile administration may have a different
impact onGnRHpulsatility,modulated by cotransmitters
such as neurokinins and dynorphins (39). There may also
be species and sex differences in the GnRH pulse regula-
tion because, unlike rodents, a GnRH surge is not oblig-
atory for the preovulatory LH surge in women (40). In
addition, the increase in secretory mass in the individual
pulses observed during kisspeptin infusion is consistent
with increased GnRH secretion.
This effect on LH pulse frequency was most convinc-
ingly demonstrated during administration of the lower
dose (1.5g/kg  h) of kisspeptin-10.Deconvolution anal-
ysis (23), like other algorithms to detect LH pulses (41), is
less sensitive with high LH secretion rates because the dis-
tinct increase in LH concentration achieved by individual
pulsatile discharges ofLHcanbeobscured.Thehighmean
LH concentrations during the higher-dose kisspeptin-10
infusion are likely to have prevented reliable analysis of
pulse frequency, leading to underestimation.
Another key observation is the relative constancy of
serum LH concentrations during kisspeptin-10 infusion,
although serum testosterone increased significantly. An-
drogens have been shown to down-regulate Kiss1 gene
expression in the nonhuman primate hypothalamus (42),
and kisspeptin-secreting neurones have been proposed to
constitute part of the pathway mediating sex steroid-neg-
ative feedback (43). Despite significant increases in serum
testosterone, althoughwithin the normal range, there was
no late decline in LH, suggesting that within the physio-
logical range, testosterone has limited ability to modulate
the ability of the GnRH neuron to respond to kisspep-
tin-10 and the pituitary gonadotroph to respond to
GnRH.
Tachyphylaxis of the GnRH/LH system during contin-
uous infusionofkisspeptin-10has alsobeendemonstrated
in primate models, with LH returning to baseline a few
hours after an initial rise (21, 44). Despite continually
infusing kisspeptin-10 for 22.5 h, we found no such de-
sensitization, and indeed LH secretion tended to in-
crease progressively. This is possibly a function of the
dose of kisspeptin used in our study being lower than
that used in the primate studies (21, 44). Tachyphylaxis
of LH response has been seen during the twice-daily
administration of kisspeptin-54 to women with hypo-
thalamic amenorrhea, but this occurred over a much
longer time period, i.e. 2 wk (9).
Stimulatory effects of kisspeptin-10 on LH, FSH, and
testosterone established in this study could inform future
studies using kisspeptin as a diagnostic or therapeutic
agent. Potent kisspeptin agonists (13) andantagonists (14)
currently being tested in animal models are amino acid
substitutions of the decapeptide sequence of kisspeptin-
10. Dose responsiveness and time course of LH stimula-
tiondemonstrated inour study couldunderpin their trans-
lation into clinical studies. Moreover, we have also
demonstrated that GnRH responsiveness is preserved in
subjects receiving kisspeptin-10 infusion and that maxi-
mal LH responses seen with kisspeptin-10 are consider-
ably lower than that achieved with GnRH. Therefore,
kisspeptin-10 might provide a more physiological stimu-
lation of the human reproductive axis with potential ther-
apeutic advantages in stimulation of ovulation.
Our study protocols did not incorporate measurement
of kisspeptin immunoreactivity for two reasons. With the
expected very short plasma half-life of kisspeptin-10 (12),
the postinjection blood sampling schedule would need to
include samples much earlier and more frequently than at
10 min for accurate analysis. Moreover, immunological
assays canpotentially give false-positive results in thepres-
ence of cleavage products of the peptide because nonspe-
cific binding of kisspeptin antibodies is well established
(42). Because the blood samples were not processed ap-
propriately, post hoc immunoassays could not be carried
out either. Mass-spectroscopic assays of serum samples
for kisspeptin 10 at various time points during the 4 g/
kg  h kisspeptin-10 infusion were therefore attempted,
but concentrations of kisspeptin-10 and its cleavage prod-
ucts (kisspeptin-9, -7, or -4)were below the detection limit
(1 ng/ml) at almost all time points, most likely due to
suboptimal sample processing.
In conclusion, iv kisspeptin-10 boluses evoke rapid and
potent LH secretion in men. Continuous infusion of kiss-
peptin-10 increases mean LH, LH pulse frequency, LH
pulse size, and testosterone secretion. These data are con-
sistent with kisspeptin being a key regulator of pulsatile
GnRH secretion.
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